Donor immune cells after stem cell transplant
Part of Blood & lymphatic, Cancer clinical trials.
This trial tests a new type of donor immune cell (called iNKT cells) given after a stem cell transplant to help prevent the cancer from coming back. It is for people with certain blood cancers who are already scheduled to have a stem cell transplant.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You must be 18 years or older.
- You must be planning to receive a stem cell transplant from a donor (any type of donor is okay).
- You must have a diagnosis of AML, CML (in certain phases), MDS, ALL (with high-risk features), or be having a transplant as standard care.
- You must be in reasonably good health, able to do most daily activities (performance status score above 70).
- You must not have primary myelofibrosis (during the first part of the study, but may be eligible later).
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests an additional immune therapy made from donor natural killer (NK) cells given around the time of a special stem cell transplant for children and young adults with high-risk acute myeloid leukemia (AML). It aims to help prevent the leukemia from coming back or not responding after transplant.
This trial tests whether giving specially trained natural killer (NK) cells after a stem cell transplant can help prevent relapse in people with high-risk blood cancers like AML, MDS, or MDS/MPN. You receive one infusion of these cells about a week after your transplant.
This trial tests whether giving donor natural killer (NK) cells after a stem cell transplant can help prevent leukemia from coming back. It is for people aged 14-25 with certain hard-to-treat leukemias who are already getting a stem cell transplant from a related donor.
This trial tests an injection of donor-derived immune cells (called RC1012) to lower the chance of AML coming back after an allogeneic stem cell transplant. It is aimed at people at higher risk of relapse once the transplant is completed.
This trial tests donated “natural killer (NK) cells,” a type of immune cell, in children and young adults with AML that has come back or did not respond to treatment. It mainly looks at safety and also studies whether the treatment can help control the leukemia.
This early trial studies adding special immune cells called “natural killer cells” after a half-matched stem cell transplant for AML or MDS. The goal is to see if this approach improves outcomes and safety when there is no fully matched donor available.
Hear when a new Acute Myeloid Leukemia trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.